News & Events
_______
Apr 7, 2022，REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002  AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH
Pipeline

Aug. 29, 2022, SHANGHAI, CHINA

RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug discovery and development, announced completion of the first patient dosing for its next-generation EGFR TKI H002 in its H002-101CN study. The study is a multicenter phase I/IIa clinical trial in China for advanced NSCLC. H002 is a next-generation EGFR TKI discovered and developed by RedCloud Bio for treatment of prior EGFR TKI-resistant NSCLC, including those with C797S mutation.  

Mar 2, 2022, Shanghai China

-  Drug Candidate Is First From Company To Enter Phase I/IIa
   Clinical Trial
-  H002 Has Potential To Overcome Resistance Driven By
   Various EGFR C797S-Containing Mutations in Non-Small
   Cell Lung Cancer
RedCloud Bio  (the “Company”),  an innovative biotech company integrating structural pharmacology and computational approaches
to advance small molecule drug development, announced today that the US Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application, clearing the path to proceed Phase I/IIa clinical investigation of H002, a broad spectrum, highly selective, fourth-generation compound.

Jun 17, 2021 - RedCloud Bio Announced the Completion of B Round Financing of RMB100 Million, Led by CO-WIN Ventures and Followed by KAITAI Capital
Corporate News
Nov 30, 2019  Nanjing China


Dayou Capital and Sherpa Capital Invested in A Round Financing for RedCloud Bio


- Support RedCloud Bio to establish a robust small molecule drug discovery program centered around structural pharmacology approach

- Fund the Company's research centers in Beijing and Shanghai

Scientific Research

The Next-Generation EGFR Inhibitor -What’s new about it? — The Latest Development of the 4th-Generation EGFR Inhibitor from the Perspective of Structural Pharmacology by Prof. Caihong Yun
Contact Us

 

Nanjing   ｜307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District Shanghai｜Suite 901, 880 Xiangyang Road, Minhang District Beijing   ｜Suite 205, Building No.2, PKUCare Industrial Park, Changping District Website: https://www.redcloudbio.com

Follow us on WeChat: RedCloudBio
2022 © RedCloudBio Co., Ltd. All Rights Reserved